drugset / Trial / NCT07047443
SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression
Non-randomizedSequentialOpen-labelTreatment
Summary
To find the optimal dose of carboplatin combined with SHR-A1811 in her2-expressed metastatic breast cancer
Timeline
- Start
- 2025-08-01
- Primary completion
- 2027-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Trastuzumab Rezetecan | Monoclonal antibody | 4.8 mg/kg | — |